Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.65 |
| ▸ | CCNE2 | O96020 | 10/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.65 |
| ▸ | CDK2 | P24941 | 10/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 4/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273882 | 0.87 | GSK3B (0.67) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL5226361 | 0.85 | GSK3B (0.49) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL5220911 | 0.83 | GSK3B (0.76) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL5221843 | 0.83 | GSK3B (0.65) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL3277605 | 0.83 | GSK3B (0.75) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL3279262 | 0.82 | GSK3B (0.64) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3274547 | 0.82 | GSK3B (0.78) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL5218515 | 0.81 | GSK3B (0.63) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3279536 | 0.81 | GSK3B (0.67) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL3273532 | 0.81 | GSK3B (0.62) | GSK3BCCNE2CCNE1CDK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595321-B2 | Compounds having selective inhibiting effect at GSK3 | ASTRAZENECA AB (SE) | 2009-09-29 | — | — | US | claimed |
| EP-1575942-B1 | COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | claimed |
| US-20060116385-A1 | Novel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | claimed |
| JP-2006512337-A | — | — | 2006-04-13 | — | — | JP | claimed |
| EP-1575942-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004055009-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| US-20100087396-A1 | Novel Compounds Having Selective Inhibiting Effect at GSK3 | BERG STEFAN | 2010-04-08 | — | — | US | disclosed |
| US-7595321-B2 | Compounds having selective inhibiting effect at GSK3 | ASTRAZENECA AB (SE) | 2009-09-29 | — | — | US | disclosed |
| EP-1575942-B1 | COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-20060116385-A1 | Novel compounds having selective inhibiting effect at gsk3 | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| EP-1575942-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1390034-A4 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004055009-A1 | NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087396-A1 | Novel Compounds Having Selective Inhibiting Effect at GSK3 | GSK3B, GSK3A, NR5A2 | GSK3B 1/4885CCNE2 500/4885CCNE1 384/4885 |
| US-20060116385-A1 | Novel compounds having selective inhibiting effect at gsk3 | GSK3B, GSK3A, NR5A2 | GSK3B 1/4885CCNE2 416/4885CCNE1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.